Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Abdominal Trauma
Interventions
Focused Assessment with Sonography for Trauma (FAST), Bubble-Enhanced FAST (BEFAST)
Diagnostic Test · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Heart Diseases
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON], Lumason
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
West Hills, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Completed Phase 3 Interventional Results available

Contrast Enhanced Ultrasound in COVID-19

NCT04640038
Conditions
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Developmental Dysplasia of the Hip
Interventions
Intraoperative contrast-enhanced ultrasound (CEUS), Lumason
Diagnostic Test · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 24 Months
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue
Interventions
NaviFUS System, Lumason, Bevacizumab
Device · Drug
Lead sponsor
NaviFUS Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Stress Echocardiography
Interventions
perflutren lipid microsphere
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Abdominal Injury
Interventions
Lumason
Drug
Lead sponsor
David Mooney
Other
Eligibility
8 Years to 17 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • Indianapolis, Indiana + 5 more
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effectiveness of Contrast-Enhanced Ultrasound

NCT03473249
Conditions
Abdominal Injuries, Physical Abuse, Accidental Fall, Motor Vehicle Injury
Interventions
Contrast-Enhanced Ultrasound using Lumason
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cirrhosis
Interventions
Contrast-Enhanced Ultrasound, Sulfur Hexafluoride Lipid Microspheres, Ultrasound
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphedema Arm
Interventions
Lumason, Optison, Definity
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Phase 1 Interventional Accepts healthy volunteers

Applying pGz in Mitochondrial Disease

NCT05569122
Conditions
Mitochondrial Myopathies, Mitochondrial Diseases
Interventions
Cardiopulmonary Exercise Testing, pGz Bed, Gentle Jogger, Exercise Pedal, Lumason® contrast agent
Diagnostic Test · Device · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Trauma Abdomen
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON], contrast-enhanced ultrasound
Drug · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Conditions
Appendicitis Acute
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Hepatocellular Carcinoma
Interventions
Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y)
Drug · Device · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers

A Proof-of-Concept Study Evaluating LINFU™

NCT05161013
Conditions
Pancreas Adenocarcinoma, Dysplasia
Interventions
LINFU™
Diagnostic Test
Lead sponsor
Adenocyte, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sarasota, Florida
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hematoma
Interventions
CEUS or Contrast enhanced Ultrasound
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
GBM
Interventions
NaviFUS System, Lumason, Bevacizumab
Device · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Proliferative Breast Disease
Interventions
Contrast Enhanced imaging, Lumason
Diagnostic Test · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Carcinoma
Interventions
Contrast-Enhanced Ultrasound, Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres
Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Conditions
Abdominal Injury
Interventions
Lumason
Drug
Lead sponsor
David Mooney
Other
Eligibility
8 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Phoenix, Arizona • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Terminated Phase 4 Interventional Results available

Ultrasound Evaluation of Crohn's Disease

NCT03235180
Conditions
Crohn Disease
Interventions
Sulfur Hexafluoride, Ultrasound Elastography, Ultrasound Vascularity, Magnetic Resonance Enterography (MRE)
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Fibromuscular Dysplasia of Arteries, Segmental Arterial Mediolysis, Spontaneous Coronary Artery Dissection, Atherosclerosis of Artery
Interventions
Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging, 3-D Volume Ultrasound
Device · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota